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1) The increasing awareness of the involvement of NO in numerous bioregulatory pathways has also opened up new therapeutic avenues for organic nitrates and NO donors, and underscored the importance of such compounds in mimicking an endogenous NO-related response or substituting for an endogenous NO deficiency.
2) A variety of acute and chronic circulatory diseases are known which are associated with a marked degree of endothelial dysfunction and characterized by a significant attenuation of endothelial derived NO. 3, 4) An emerging therapeutic strategy is to administer physiological amounts of NO in the bloodstream or at the site of the local tissue and injured cells in order to improve diminished supplies of NO for the maintenance of cardiovascular homeostasis. The furoxan ring system (1,2,5-oxadiazole-2-oxide, furazan oxide) has been widely used as an intermediate for the synthesis of various heterocyclic compounds, 5) owing to its mysterious structure or intricate chemistry. It has been reported to possess a wide spectrum of pharmacological activities, including vasodilatory activity. [6] [7] [8] [9] [10] [11] [12] Studies have shown that furoxan derivatives are NO donors, [10] [11] [12] [13] [14] [15] [16] which generate NO or related N-oxide species in a controlled manner. These findings have prompted the inclusion of the furoxan ring in the design of NO releasing drugs. The furoxan derivatives CAS 1609 and CHF 2206 are notable examples of furoxan derivatives which have demonstrated the success of such an approach (Fig. 1) . They exert vasodilating activity with a pharmacological potency suggestive of NO donating pro-drugs (so-called NO donors). 3, 16) CHF 2206 (3-phenylsulfonyl-4-phenylfuroxan) was able to inhibit rabbit aortic ring contraction induced by norepinephrine and KCl, and the activity was independent of endothelium integrity. CAS 1609 (2-hydroxymethyl-furoxan-3-carboxamide) relaxed both potassium-depolarized and phenylephrine-contracted guinea pig vessel strips in a concentration-dependent manner.
The combination of a nitrate moiety with another pharmacologically active substructure in a single molecule has recently received particular attention. 2, 17, 18) Nicorandil is an antianginal drug, which shares properties of K ϩ channel openers and NO donors. It causes vascular smooth muscle relaxation via two main mechanisms: increasing membrane K ϩ conductance through the opening of ATP-dependent K ϩ channels leading to hyperpolarization and releasing NO elevating cyclic GMP levels by stimulating soluble guanylate cyclase. 17) Nicorandil may be the prototype of the hybrid drugs with K ϩ channel opening properties mixed with NOdependent vasodilating activities. Structurally, it is a nicotinamide derivative with a nitrate group in its chemical structure (Fig. 1) . The O-NO 2 moiety is responsible for the group's action as nitrates and also influences their potency as K ϩ nel activators.
The synthesizing of hybrid molecules of furoxan and nicorandil derivatives may prove to be a useful approach in moderating the NO releasing properties, 18, 19) so as to achieve an ideal cardiovascular drug with good selectivity, efficiency, acceptable duration of action and low toxicity.
Based on this idea, we synthesized in the present paper a series of "hybrid" drugs designed by linking the furoxan ring to nicorandil analogues and investigated their NO donating properties. The compounds are evaluated for their ability to inhibit KCl-induced contraction of rabbit aortic strips which have been denuded of endothelium. Eight compounds were identified to possess good vasodilatory activity and one of them was further tested for its hypotensive effects in anaesthesized rats. This compound was found able to significantly reduce blood pressure 3 h after administration. Its hypotensive effects can prevail for a further 3 h. The results indicate that the present approach of molecular hybridization is a viable step in designing active NO releasing compounds.
Results and Discussion
Chemistry The furoxan-nicorandil derivatives were synthesized according to the pathways shown in Chart 1. 3-Methylfuroxan-4-carbaldehyde (8) was synthesized from the reaction of dinitrogen trioxide (generated from sodium nitrite and acetic acid) on crotonaldehyde. 19, 20) The aldehyde was oxidized to the acid (3-methylfuroxan-4-carboxylic acid (9) using Jones' reagent, and the resulting acid was converted to the reactive acid chloride using thionyl chloride. The acid 1, 2, 3a-e, g; 4a-c, e) and amines (5a, b, d-j; 6a, b, d,  e, g, i; 7a, b, d-j) to give the desired compounds (11; 12;  13a-e, g; 14a-c, e; 15a, b, d-j; 16a, b, d, e, g, i; 17a, b, d-j) ( Table 1) .
The alcohols N-(2-hydroxyethyl)nicotinamide (1) and N-(2-hydroxyethyl)iso-nicotinamide (2) were synthesized by reacting the ethyl esters of nicotinic acid and isonicotinic acid with ethanolamine in chloroform. The alcohols in the 3(ae, g) series are N-(2-hydroxyethyl)benzamides, with monoor di-substitution on the phenyl ring. The substituents on the ring were predominantly electron withdrawing groups (nitro, chloro, bromo) at the 3, 4 or 3, 4 positions, with the exception of the methoxy substituent. These were prepared from the reaction of ethanolamine and the ethyl ester of the substituted benzoic acid in refluxing chloroform. The alcohols in the 4(a-c, e) series are ring substituted N-(3-hydroxypropyl)-benzamides and these were prepared from the reaction of propanolamine and the ethyl ester of the substituted benzoic acid in refluxing chloroform. The amines in series 5, 6, 7 are substituted N- (2-aminoethyl) benzamides, N-(3-aminopropyl)-benzamides and N-benzoylpiperazines, respectively. They were prepared from the reaction of ethylenediamine, 1,3-diaminopropane or piperazine with substituted benzoyl chlorides. The main difficulty encountered in the synthesis of these compounds is the reactivity of the amino groups in ethylenediamine, diaminopropane and piperazine, resulting in acylation of both amino groups by acid chloride. Various approaches can be used to prevent this from happening: one of the amino groups can be protected by formylation or with an ethoxycarbonyl group, or by conversion to a salt. All of these methods necessitate additional reaction steps and careful control of reaction conditions. Alternatively, the diamine may be titrated with the acyl chloride to ensure that the reaction is terminated only after 1 eq of the reagent has been consumed, or by reacting the diamine with the substituted benzoic acid using dicyclohexylcarbodiimide (DCC) as condensing agent. However, both approaches present considerable difficulties and it was not possible to obtain the monoacylated product by these techniques; this may be due to the fact that both amino groups are of very similar reactivity. It was subsequently found that the problem could be averted by converting the diamino compound into the monoamine salt form, or by carrying out the reaction in a weakly acidic solvent like acetic acid which serves to reduce the nucleophilicity of the amino group by salt formation. After numerous trials, it was found that monoacylation could be achieved if the reaction was carried out using a ratio of 2 parts acyl chloride to 3 parts diamine compound in acetic acid as solvent, and at room temperature. The monoacylated compounds were obtained as hydroscopic solids which were used immediately for the next step of the reaction.
Condensation of the alcohols (1, 2, 3a-e, g, 4a-c, e) and amines (5a, b, d-j, 6a, b, d, e, g, i; 7a, b, d-j) with the furoxan (10) was carried out in either chloroform or dichloromethane in the presence of triethylamine, which served a catalytic function or reacted with HCl released during the reaction. The final compounds were characterized by IR, 1 H-NMR, and high resolution mass spectroscopy (HR-MS), and the analytical results were compatible with the proposed structures (Table 2) .
Structure-Activity Relationship
To investigate the vasorelaxing action of the synthesized compounds, different KCl-induced contraction systems were proposed. The inhibitory effect at high KCl concentration (80 mM) was not strong and the highest inhibition was only 9.2Ϯ2.9. Thus, a low KCl concentration (30 mM) system was used, and it was found that most of the compounds demonstrated the ability to cause a relaxation in the aorta precontracted with KCl; the highest inhibition was 40.6Ϯ9.4. The pharmacological data are shown in Table 3 . Eight compounds reduced the KCl (30 mM)-induced contraction by at least 30%. They were 13a,  14c, 15a, 15e, 15g, 16a, 16e, 17i , all are substituted phenyl derivatives. The pyridyl derivatives 11 and 22 demonstrated significantly less activity. Of the 8 substituted phenyl derivatives, there is a significant preponderance of rings substituted with electron withdrawing groups (nitro or halogen) at the meta and/or para positions. The only exception is 17i which has an electron donating methoxy function at the para position. Other than this feature, the presence of an amide or ester function in the side chain, the number of methylene units (2 or 3) between the carbonyl groups or the presence of a piperazine ring did not appear to be important determinants of activity.
Following the demonstration of functional vasodilatory ac- tivity on the thoracic aorta whose endothelium was denuded, the effects of the compounds were investigated on the blood pressure of anaesthesized rats. Compound 17i was chosen as a representative compound for this investigation and was found to cause a gradual reduction in the blood pressure (systolic, diastolic and mean arterial pressures) of the animal, which reached a plateau after 3 h. The reductions in these three arterial pressures were 30, 20 and 26 mmHg, respectively, after 3 h. The reduction in blood pressure was maintained over a period of 6 h thereafter. Therefore, it can be concluded that 17i demonstrates a gradual and sustained hypotensive action which may be related to a measured release of NO from the furoxan moiety. This is a desirable feature which could be exploited in the drug design of potential NO donors.
Conclusion
Thirty six furoxan-nicorandil derivatives have been synthesized successfully by conventional chemical methods, and were investigated for their ability to reduce KCl-induced contraction in the isolated rabbit thoracic aorta. All except 2 of the compounds were found to cause a relaxation in the aorta precontracted with KCl to varying degrees. Of the active compounds, 8 analogues caused at least 30% reduction of the control KCl-induced contraction; the most active compound was 16e which reduced the contraction by 40.6% (30 mM KCl). A representative compound 17i (which caused 36.3% reduction in the KCl-induced contraction) was tested for hypotensive effects in the anesthesized rat. It was seen that 17i caused a gradual and sustained reduction in blood pressure. Based on these preliminary results, it would seem that the furoxan-nicorandil derivatives are a useful lead in the design of NO-donor compounds for hypertesion.
Experimental
General Melting points were determined with a capillary apparatus and were uncorrected. The compounds were routinely characterised by IR spectrophotometry (Perkin-Elmer Model 983, KBr tablet). The 1 H-NMR spectra were recorded in acetone-d 6 , chloroform-d 6 /CDCl 3 or dimethyl sulfoxided 6 /DMSO-d 6 . Chemical shifts were expressed in d (ppm) units (JEDL-FX-90Q Fourier transform NMR spectrometer, Si(Me) 4 /TMS as internal standard). For all final compounds, HR-MS spectra were carried out on a Finnigan FTMS-2000 instrument and were in agreement with the proposed structures. Column chromatography was performed on silica gel (China Qingdao Marine Chemical Company, 100-200 mesh ASTM) with the indicated solvent system. Thin layer chromatography (TLC) was carried out on 5ϫ20 cm plates and 2.5ϫ7.5 cm microscope slides, which were coated with Qingdao Marine silica gel GF 254 (400 mesh) and 0.8%-1% CMC-Na, activated and dried for 1-2 h at 100-110°C, then stored in a dryer. Anhydrous magnesium sulphate was used as drying agent for the organic layers. Petroleum ether (30-60°C) and dicholoromethane were used for chromatography purification and crystallization. Solvent was removed under reduced pressure at room temperature. Intermediates 8-10 were synthesised according to methods reported in the literature. 19, 20) N-(2-Hydroxyethyl)nicotinic Amide (1) Concentrated sulphuric acid (5 ml) was added dropwise to a stirred mixture of nicotinic acid (0.2 mol, 25 g) in anhydrous ethanol and cyclohexane (1 : 1, 200 ml). A water separator condensor was attached. The temperature was raised slowly and the mixture was refluxed for 3-6 d with stirring. Removal of the solvent under reduced pressure gave a light-yellow oil which was added to saturated Na 2 CO 3 solution with stirring until a pH value of 7 was reached. The mixture was then extracted with ethoxyethane, and the combined organic phase was washed with saturated NaCl, dried with MgSO 4 and evaporated. The nicotinic acid ester was obtained as pure colourless oil after vacuum distillation. Then nicotinic acid ester (0.05 mol, 7.2 g) and ethanolamine (5 ml) were added to chloroform with stirring. The mixture was refluxed for 3-4 h, and allowed to stand overnight before the solvent CHCl 3 , ethanol formed from reaction and the excess of ethanolamine were evaporated under reduced pressure. A white hard solid was obtained, which gave white crystals when recrystallized with acetone. Yield 96%, mp 90-92°C.
3-Methyl-4-[2(3-pyridineformamido)ethoxycarbonyl]furoxan (11) 1 (0.02 mol, 3.3 g), CH 2 Cl 2 (80 ml) and triethylamine (3 ml) were mixed and stirred at a temperature below 30°C. A light-yellow solution was obtained. A solution of compound (10) (0.02 mol) in tetrahydrofuran (THF) was added dropwise at room temperature and a colour change (yellow to black-brown) was observed. The reaction was exothermic and heat was exuded. The mixture was stirred at room temperature for 16 h, after which water was added. The organic phase was washed with water, decolourised with active carbon and filtered. The solution was evaporated to dryness under reduced pressure to give (11) as a pure brown solid. Yield 54.5%. mp 112-114°C. N-(2-hydroxyethyl)isonicotinic Amide (2) Concentrated sulphuric acid (1.5 ml) was added dropwise to a stirred mixture of isonicotinic acid (0.1 mol, 13.0 g) in absolute ethanol (30 ml). The mixture was refluxed for 10 d. A hard white solid was formed after the ethanol was evaporated in vacuo. The solid dissolved with the addition of saturated Na 2 CO 3 , and the alkaline solution was then extracted with ethoxyethane. The organic layer was washed with saturated NaCl solution, dried, evaporated and then vacuum distilled, resulting in a pale-yellow oil of ethyl isonicotinate. A mixture of the ethyl isonicotinate (0.02 mol, 3.3 g), ethanolamine (3.0 ml) and chloroform (10 ml) were refluxed for 3-4 h with stirring, after which the solvent chloroform and ethanol were removed in vacuo. Ethoxyethane and acetone were then added and a white precipitate was obtained, filtered off, washed with chloroform, acetic ester, acetone, and dried to give the title compound. Yield 96%, mp 130-132°C.
3-Methyl-4-[2(4-pyridineformamido)ethoxycarbonyl]furoxan (12)
A solution of compound (10) (0.01 mol) in THF was added dropwise to a stirred mixture of 2 (0.01 mol, 1.6 g) in THF (50 ml) and triethylamine (1 ml) at room temperature. The stirring was continued for 6 h, after which the solvent was evaporated in vacuo to give a brown sticky paste, which was poured into water. The solution was filtered to remove some pale brown precipitate. The aqueous solution was extracted with CH 2 Cl 2 , and the combined organic solution was washed with saturated NaCl, decolorized with 400 mesh silica gel, dried and evaporated to give the title compound as a white solid. It was then purified by washing with ethanol and ethoxythane. Yield 50.5%. mp 168-170°C. 1 General Method for the Preparation of N-Substituted Benzoylpiperazine (7a,b, d-j) Hydrate piperazine (0.006 mol, 0.62 g) and acetic acid (50 ml) were mixed, immediately producing some gaseous fumes and heat was released. The mixture was then stirred until a colourless solution was obtained as it cooled. A solution of the substituted benzoic acid chloride (0.006 mol) in THF (2 ml) obtained by refluxing the relating substituted benzoic acid in thionyl chloride was then added dropwise to the stirred mixture which became turbid. The stirring was continued for about 60 min at room temperature, water was added and the pH was adjusted with NaOH solution to 12. The solution was filtered to remove some white or pale-brown undissolved substances. The aqueous solution was extracted with chloroform, the organic solution was then washed with water or saturated NaCl solution, dried and evaporated in vacuo to give the desired compound (7a, b, d-j) , which was then processed quickly for the next step of the reaction. (17a, b, d-j) A solution of compound 10 (0.006 mol) in THF was added dropwise to a stirred mixture of 7a, b, d-j (0.006 mol) in CH 2 Cl 2 (60 ml) and N (C 2 H 5 ) 3 (1 ml). Stirring was continued for about 6 h at room temperature, after which the resulting mixture was washed several times with water, 10% HCl and saturated NaHCO 3 consecutively. The organic layer was then decolorized with active carbon, dried and evaporated to afford a solid compound which was further purified with acetone or ethanol to give the final compounds (17a, b, d-j) .
General Method for the Preparation of N-(3/4-Substituted-benzoyl)-N-[3-methylfuroxanyl-4-carbonyl]piperazine
The physical data of the synthesised compounds (17a, b, d-j) are given in Table 2 . The compounds are N- (3- 
General Method for the Preparation of 3-Methyl-4-[2-(3/4-substituted benzoyl amino) ethylaminocarbonyl]furoxan (15a, b, d-j) Ethylene diamine (0.017 mol, 1.0 g) and acetic acid (50 ml) were slowly mixed together, a large amount of white gas was produced and the reaction was exothermic. A white solid was initially formed but dissolved gradually to form a colourless solution, as it cooled to room temperature. The corresponding benzoic acid chloride derivative (0.01 mol) was then added dropwise with stirring over 30 min at room temperature. After 2 h water was added to the mixture, and the pH adjusted to 12 with NaOH solution. The solution was filtered to remove some white precipitate and the aqueous filtrate was extracted with chloroform, the organic phase was washed with saturated NaCl, dried and evaporated under reduced pressure to afford the intermediate N-(2-aminoethyl)-substituted benzoylamide (5a, b, d-j) which was used immediately for the next step of the reaction. A solution of compound 10 (0.01 mol) in THF (2 ml) in the presence of triethylamine (0.5 ml) was added dropwise at room temperature to a stirred solution of 5a, b, d-j in CH 2 Cl 2 .
The stirring was continued 3-6 h and then the reaction mixture was poured into water. The organic layer was washed several times with water, decolorised with active carbon, dried and evaporated under reduced pressure to give the desired derivatives (15a, b, d-j) which were recrystallized with ethanol. The physical data of the synthesized compounds (15a, b, d-j) are given in Table 2 13a-e, g ) Concentrated sulphuric acid (1 ml) was added dropwise to a stirred mixture of the substituted benzoic acid (0.02 mol) in absolute ethanol (100 ml). After refluxing for 8 h, the solution was cooled to room temperature, and cyclohexane (60 ml) was added. The mixture was distilled to evaporate the water formed from the reaction, as well as the solvents cyclohexane and ethanol. A pale-yellow sticky residue was exuded, water was added and the mixture was extracted with ethoxyethane. The organic solution was washed several times with saturated NaCl and water, dried and evaporated in vacuo to give the substituted benzoic acid ester. The ester was reacted with ethanolamine (0.02 mol, 1.3 g) in chloroform with stirring. The mixture was then refluxed for 8 h, after which the organic solvents were removed in vacuo to give a pale-brown oil which became a sticky solid on cooling in the refrigerator. Subsequent grinding of the sticky solid with some acetone and ethoxyethane gave a white solid which was the intermediate N-(2-hydroxyethyl)-substituted-benzoylamides  (3a-e, g ). These intermediates were recrystallized with one of the following solvents: acetone, acetic ester, ethoxyethane, or petroleum ether. A solution of 10 (0.01 mol) in THF (2 ml) was added dropwise to a stirred mixture of 3a-e, g in dichloromethane (60 ml) in the presence of triethylamine (1 ml). The stirring was continued for 3-6 h, after which the reaction mixture was poured into water. The separated organic solution was washed several times with water, decolorized with active carbon, dried and evaporated under reduced pressure. The expected final derivatives 3-methyl-4-[(2/3-substituted benzoylamino)alkyloxylcarbonyl]furoxan (13a-e, g) were obtained after recrystallization with ethanol or ethoxyethane. The physical data of the synthesized compounds (13a-e, g) are given in Table 2 Pharmacology. Experiments on Denuded Thoracic Aorta Isolated from Rabbits The thoracic aorta was isolated from male or female rabbits weighting 1.8-2.5 kg, which were sacrificed by a sharp blow on the head. Helicoid strips were prepared according to known methods and mounted in an organ bath containing Krebs-Henseleit buffer solution pH 7.4 of the following composition: NaCl, 120; KCl, 4.8; CaCl 2 , 2.5; MgSO 4 · 7H 2 O, 1.4; KH 2 PO 4 , 1.2; NaHCO 3 , 25; glucose 11 mmol/l; Na 2 EDTA 13.4 mmol/l. The tissue was maintained at 37°C and aerated with 95% O 2 -5% CO 2 . After an equilibrium period of 2 h, the aortic strips were contracted by addition of either 30 or 80 mM KCl solution. The sample (10 mM) was then added and its effect on KCl-induced contraction was monitored. Each experiment was repeated 3 times. The drug was dissolved in DMSO-saline, and the volume ratio of DMSO did not exceed 0.5% of the bath volume. The effect of the drug on the aorta precontracted with KCl was expressed as an inhibitory ratio which is given as Eq. 1.
(1)
Effect of Blood Pressure in Anaesthesised Rats
Male or female rats weighting about 250 g were anesthesised and carefully dissected to expose the carotid artery. The artery was cannulated and a pressure transducer connected to a Grass Polygraph recorder was attached. The systolic, diastolic and mean arterial (MAP) pressures were monitored until steady values were obtained. The drug was administered via intravenous injection at a dose of 1.5 mg/kg and the pressures were monitored over a period of 6 h.
